摘要
目的:探讨黄芪多糖(APS)联合碘-125(I125)治疗中晚期非小细胞肺癌(NSCLC)的临床疗效及作用机制。方法:将60例中晚期NSCLC患者随机按住院前后顺序分为观察组和对照组各30例,对照组采用I125粒子植入方法,观察组在对照组治疗的基础上加用APS 250 mg,静脉滴注,1次/d。疗程42 d。观察治疗前患者瘤体大小,进行治疗前后KPS评分,检测治疗前后细胞免疫功能(NK,CD+3,CD+4,CD+8)和血清癌胚抗原(CEA)和细胞角蛋白19片段(CYFRA-21-1)水平。结果:治疗后观察组和对照组总有效率分别为83.33%和73.33%,两组比较差异无显著性意义;治疗后观察组卡氏评分提高+稳定率为90.0%,优于对照组的63.3%(P<0.01);治疗后对照组NK,CD+3,CD+4,CD+8及CD+4/CD+8变化不明显,治疗后观察组NK,CD+3,CD+4及CD+4/CD+8上升并高于对照组,CD+8下降并低于对照组(P<0.01);两组血清CEA,CYFRA-21-1水平均较治疗前下降,治疗后观察组低于对照组(P<0.01)。结论:APS联合I125治疗中晚期NSCLC,能提高患者生活质量,提高患者免疫功能,并具有一定的抗肿瘤作用,对I125起到增效作用,值得进一步研究。
Objective： To investigate the effect of Astragal Polysaccharides combined with Iodine-125 （1115） in the treatment of advanced non small cell lung cancer （NSCLC） clinical curative effect and mechanism of action. Method： A total of 60 cases of patients of advanced NSCLC were randomly by digital divided into observation group and control group with 30 cases in each group, the control group using 1125 particle implantation method, the observation group was treated with Astragal Polysaccharide （APS） 250 mg, once a day. The course of treatment was 42 days. Before treatment in patients with tumor size, KPS score before and after treatment, the cell immune function were detected before and after treatment （NK, CD3＋ , CD4 , CDs＋ ） and serum carcinoembryonic antigen （CEA） and cytokeratin 19 fragment （CYFRA-21-1） level. Result： after treatment, the observation group and the control group the total effective rate were 83.33% and 73.33% , no significant difference between the two groups; after treatment, the observation group KPS increase and stable rate were 90.0% , more than 63.3% of control group （P 〈 0.01 ） ; the control group after treatment NK, CD3^＋ , CD4^＋ , CD8^＋ and CD4^＋/CD8^＋ did not change significantly, after treatment were observed in group NK, CD3^＋, CD4 and CD4/CDs increased and higher than that of the control group, CD8 decreased and was lower than the control group （P 〈0.01 ） ;serum CEA, CYFRA- 21-1 levels in the two groups were decreased than that before treatment, after treatment, the observation group than in the control group （P 〈 0.01 ）. Conclusion： APS combined with I^125 in the treatment of advanced NSCLC, can improve the quality of life of patients, improve immune function, and has certain anti tumor effect and synergistic effect on the I^125, worthy of further study.
出处
《中国实验方剂学杂志》
CAS
北大核心
2014年第1期189-192,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
云南省"十二五"特色优势"中西医结合"学科资助项目(30160800101)
关键词
中晚期非小细胞肺癌
碘-125
注射用黄芪多糖
细胞免疫
advanced non-small cell lung cancer
Iodine-125 （I^125）
Astragalus Polysaccharide injection
cell immune
